Kiniksa pointed to Arcalyst's success with its most recent approval, specifically for heart disorder pericarditis, as the ...
4d
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –– ARCALYST 2026 expected net ...
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported first-quarter 2026 results and provided updates on commercial ...
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is one of the best drug stocks to buy according to analysts. Kiniksa ...
Kiniksa Pharma (KNSA) stock hit a 52-week high as the company reported better-than-expected Q1 2026 thanks to Regeneron (REGN ...
Kiniksa Pharmaceuticals International, plc reported past first-quarter 2026 results with revenue of US$214.27 million and net income of US$22.59 million, alongside basic earnings per share from ...
Guidance and language shifted from reiterating 2026 net revenue guidance of $900 million to $920 million to raising it to $930 million to $945 million, attributed to Q1 prescribing breadth/depth.
Credit: Getty Images. Arcalyst is a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1. The Food and Drug Administration (FDA) has approved Arcalyst ® (rilonacept) ...
Regeneron announced that its Phase 3 study of Arcalyst (rilonacept injection) met its primary and secondary endpoints for the prevention of gout attacks. This trial, known as PRE-SURGE 1 (PREventative ...
TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...
TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results